Replies to post #373628 on Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

Brilacidin may have had twice the number of AEs but Brilacidin also had three times the number of patients.

It's a useless comparison. AEs don't matter because most of them are harmless or near harmless - in the context of moderate-severe COVID they don't matter.

Tingling fingers and toes for a few hours is not a problem when the alternative is that the only thing that soothes the burning of your lungs is the viscous fluid that slowly accumulates and drowns you to death.

[sunspotter]

"In the ABSSSI trial, Brilacidin may have had twice the number of AEs but Brilacidin also had three times the number of patients."

Percentages, familyman, percentages.

The percentage of brilacidin patients who experienced at least one adverse events was 84.3%.


The percentage of daptomycin patients who experienced at least one adverse events was 46%.

84.3 divided by 46 is 1.8, or roughly double.

I do hope that's clear.